Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EVIDENT

Financiado

Cerrado

Ebola Virus Disease correlates of protection determinants of outcome and cli...

Ebola Virus Disease correlates of protection determinants of outcome and clinical management The Ebola virus disease (EVD) epidemic in West Africa is not under control. This proposal has immediate, mid-term and long-term objectives to combat the current and future EVD epidemics. Objectives with immediate impact are: (i) P... ver más

31/10/2016

BNI

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

BERNHARDNOCHTINSTITUT FUER TROPENMEDIZIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 12 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-10-31

DIGITAL-2024-CLOUD-AI-06-HEALTHRECORD: Demonstrating the in-service use of... Expected Outcome:Deliverables

I+D

Cerrada hace 8 meses

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

12 Participantes

BNI

481.66K€ | Lider

EURICE EUROPEAN RESEARCH AND...

163.38K€ | Participante

406.94K€ | Participante

BUNDESMINISTERIUM FUER GESUN...

73.63K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Ebola_Tx Emergency evaluation of convalescent blood and plasma for Eb... 3M€ Cerrado

SUPPORT-E SUPporting high quality evaluation of COVID 19 convalescent... 4M€ Cerrado

EBOVAC1 Development of a Prophylactic Ebola Vaccine Using an Heterol... 98M€ Cerrado

VSV-EBOPLUS SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV... 15M€ Cerrado

EBOVAC3 Bringing a prophylactic Ebola vaccine to licensure 51M€ Cerrado

IF-EBOla Control of the Ebola Oubreak by both innovative Ultrasensiti... 2M€ Cerrado

Duración del proyecto: 22 meses Fecha Inicio: 2014-12-03
Fecha Fin: 2016-10-31

Líder del proyecto

BERNHARDNOCHTINSTITUT FUER TROPENMEDIZIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The Ebola virus disease (EVD) epidemic in West Africa is not under control. This proposal has immediate, mid-term and long-term objectives to combat the current and future EVD epidemics. Objectives with immediate impact are: (i) Providing key information needed to implement efficient convalescent plasma treatment and a toolkit to determine the suitability of plasma for treatment; (ii) Providing key information needed to estimate the efficacy of experimental vaccines, including correlates of protection at T cell level; (iii) Improving supportive treatment of patients and reducing hospital case fatality rate by providing information on biomarkers and relevant co-infections; (iv) Monitoring development of mutations in Ebola virus (EBOV) genomes during the epidemic and enhancing our preparedness to determine the relevance of these changes in experimental systems; and (v) Protecting health care workers and communities by providing information on virus shedding in body fluids and estimation of infectiousness in various stages of EVD. Objectives with mid to long-term impact are: (i) Provide information on pathophysiological changes and immunological determinants to infer new immunotherapeutic strategies for treatment of EVD; and (ii) Strengthening cooperation of biosafety level 4 (BSL-4) facilities and building a pan-European research area in the field of highly pathogenic viruses as envisaged in the ‘European Research Infrastructure on Highly Pathogenic Agents’ project. The concept of EVIDENT is to scientifically exploit specimens collected from EVD patients during outbreak response and field research. We will use state-of-the-art methodologies within the EU BSL-4 facilities to gather new and outbreak-relevant knowledge on B and T cell immunology, biomarkers, virus evolution, virulence determinants, and transmission of EBOV. The consortium contributes to the outbreak response since March 2014 and is competent to implement a project in the outbreak area.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores